About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2444 blog entries.

Advaxis requests orphan drug designation for treatment of HPV-associated head and neck cancer with ADXS-HPV

Source: www.marketwatch.com Author: press release Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated head and neck cancer. There are about 50,000 new cases of head and neck cancer annually, with about 15,000 deaths. HPV infection is estimated to account for 20-50% of current incidence. Orphan Drug Designation is granted to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people in the United States. Orphan Drug Designation entitles the sponsor to clinical protocol assistance with the FDA, as well as federal grants, tax credits, and a seven year market exclusivity period. "HPV-associated head and neck cancer is growing at an epidemic rate in the United States and other regions throughout the world. According to the U.S. Centers for Disease Control and Prevention (CDC), over 80% of new cases occur in men, who are not typically part of HPV vaccination programs," commented Dr. Robert Petit, Chief Scientific Officer of Advaxis. "Data from our Phase 2 study in recurrent cervical cancer show that ADXS-HPV is an active treatment in this HPV-associated cancer. We believe that ADXS-HPV immunotherapy will show similar activity in HPV-associated head and neck cancer, given the shared causality of the cancers. We have one ongoing Phase 1/2 study in [...]

2013-06-12T07:27:15-07:00June, 2013|Oral Cancer News|
Read More

Why HPV vaccination makes a difference against cancer

Source: www.cbsnews.com Author: Michelle Castillo Michael Douglas' frank discussion about the human papillomavirus (HPV) and oral cancer has put a spotlight on the dangers of the sexually transmitted virus. While using a condom may reduce risk for HPV, doctors are reminding people that the best way to protect oneself from the disease that can potentially lead to cancer is to get vaccinated at an early age and, if possible, go for routine screenings. HPV is a group of more than 100 very common viruses, about 40 of which can be transmitted sexually, according to the U.S. Department of Health and Human Services Office on Women's Health. Approximately 79 million Americans are currently infected with an HPV strain, the Centers for Disease Control and Prevention reports, and nearly all sexually active men and women will get one type of sexually transmitted HPV in their lifetime. Specifically, 20 million people in the U.S. between the ages of 15 to 49 are infected with a genital HPV at any given time, and about half of men and women can expect to be infected with genital HPV in their lifetime. "HPV is ubiquitous in our population," Dr. Lori Wirth, medical director of the Center for Head and Neck Cancers center at Massachusetts General Hospital in Boston, explained to CBSNews.com. "Anyone who has led a normal sex life will get HPV, and develop antibodies to the virus. But, a minority of people who have contact with the virus who don't effectively clear the virus from [...]

2013-06-12T07:21:26-07:00June, 2013|Oral Cancer News|
Read More

Fact check: Michael Douglas on HPV and throat cancer

Source: www.huffingtonpost.com Author: Meredith Melnick A Michael Douglas interview in The Guardian caused waves when the publication reported that the "Behind the Candelabra" star revealed HPV, the human papilloma virus, to be the cause of his stage-4 throat cancer diagnosis in 2010. "Without wanting to get too specific, this particular cancer is caused by HPV, which actually comes about from cunnilingus," Douglas allegedly told The Guardian. Douglas, through his publicist, has said that the statement was misinterpreted: He wasn't saying that his cancer was caused by the sexually transmitted disease -- merely that many cancers like his are HPV-positive. As The Daily Beast points out, there is scant research evidence to directly link the act of cunnilingus with HPV infection. But regardless of the details of his own cancer, the actor is right about one thing: A growing majority of oral cancer cases are caused by HPV. While most strains of HPV clear up on their own, the sexually transmitted disease is responsible for an array of cancers. As Douglas describes, it's true that oral sex is an avenue through which a person can contract HPV and especially the strains, HPV-18 and HPV-16, the latter of which is responsible for half of oral cancer cases, according to the National Cancer Institute. HPV-16, HPV-18 and some less-common strains can also cause cancers of the cervix, vagina, vulva, anus and penis. Douglas' experience follows trends in cancer diagnosis, according to a January report from the American Cancer Society, which found a rise [...]

2013-06-04T07:22:57-07:00June, 2013|Oral Cancer News|
Read More

Oral cancer prognosis based on clinicopathologic and genomic markers using a hybrid of feature selection and machine learning methods

Source: 7thspace.com Author: staff Machine learning techniques are becoming useful as an alternative approach to conventional medical diagnosis or prognosis as they are good for handling noisy and incomplete data, and significant results can be attained despite a small sample size. Traditionally, clinicians make prognostic decisions based on clinicopathologic markers. However, it is not easy for the most skilful clinician to come out with an accurate prognosis by using these markers alone. Thus, there is a need to use genomic markers to improve the accuracy of prognosis. The main aim of this research is to apply a hybrid of feature selection and machine learning methods in oral cancer prognosis based on the parameters of the correlation of clinicopathologic and genomic markers. Results: In the first stage of this research, five feature selection methods have been proposed and experimented on the oral cancer prognosis dataset. In the second stage, the model with the features selected from each feature selection methods are tested on the proposed classifiers. Four types of classifiers are chosen; these are namely, ANFIS, artificial neural network, support vector machine and logistic regression. A k-fold cross-validation is implemented on all types of classifiers due to the small sample size. The hybrid model of ReliefF-GA-ANFIS with 3-input features of drink, invasion and p63 achieved the best accuracy (accuracy = 93.81%; AUC = 0.90) for the oral cancer prognosis. Conclusions: The results revealed that the prognosis is superior with the presence of both clinicopathologic and genomic markers. The selected features can [...]

2013-06-03T10:50:00-07:00June, 2013|Oral Cancer News|
Read More

Study reveals genetic diversity within tumors predicts outcome in head and neck cancer

Source: bionews-tx.com Researchers at the Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear Infirmary have developed a new way to predict the survival rate of patients who have squamous cell carcinoma of the head and neck, thanks to a study partially funded by a CPRIT grant. One of the problems with treating cancer is the degree of genetic heterogeneity within a tumor. What this means is that there are sub populations of tumor cells within a given tumor that have different mutations. This makes the cancer difficult to treat because some cells due to their different mutations will be resistant to the same treatment. According to Edmund Mroz, PhD at the MGH center for Cancer Research (lead author of a report in Cancer on May 20, 2013), this new method of measuring genetic heterogeneity can be applied to a wide range of cancers. (Additional co-authors included Curtis Pickering, PhD, and Jeffrey Myers, MD, PhD, both from the University of Texas M.D. Anderson Cancer Center.) Prior to this study, genes and proteins that are involved with treatment resistance have been identified, however, there has been no way to measure tumor heterogeneity to predict patient survival. Mroz and his group of researchers working in the lab of James Rocco, MD, PhD at MGH developed this new measure by looking at advanced gene sequencing data to calculate a number that indicates the genetic variance found in sub populations of cells within a tumor. They dubbed this new procedure as the mutant-allele tumor [...]

2013-05-25T14:02:13-07:00May, 2013|Oral Cancer News|
Read More

Heartburn and throat cancer: is there a link?

Source: www.huffingtonpost.com Author: staff Heartburn may raise a person's risk for throat cancer, but it seems that antacids could have a protective effect, according to a new study. The research, published in the journal Cancer Epidemiology, Biomarkers & Prevention, shows that people with a history of frequent heartburn, also known as acid reflux, have a 78 percent higher risk of developing vocal cord or throat cancers. But they also found that for people with frequent heartburn, taking antacids can lower risk of these cancers by 41 percent. "Additional studies are needed to validate the chemopreventive effects of antacids among patients with frequent heartburn," study researcher Scott M. Langevin, Ph.D., a postdoctoral research fellow at Brown University, said in a statement. "The identification of gastric reflux as a risk factor for throat and vocal cord cancers, however, may have implications in terms of risk stratification and identification of high-risk patients." The study included 631 people who were part of a case-control study in Boston, 468 of whom had throat cancer and 163 of whom had vocal cord cancer, as well as 1,234 people with no cancer history. Researchers analyzed family history of cancer, smoking history and drinking history of all the study participants, as well as presence of HPV 16 viral protein antigens since HPV can cause some head and neck cancers. Researchers found that the increased risk for throat and vocal cord cancers was higher among the people experiencing frequent heartburn, even when they had no history of smoking or [...]

2013-05-25T13:52:08-07:00May, 2013|Oral Cancer News|
Read More

Public lacks awareness of head and neck cancer

Source: www.alberniportal.ca Author: Leatitia Michael A survey reveals that the general public, including those who smoke, do not know very much about oral, head, and neck cancer (OHNC). There were nearly 40,000 new cases of oral, head and neck cancer diagnosed last year in the USA, of which 85 per cent could be linked to tobacco use and heavy alcohol consumption. Yet, according to a survey from the Medical University of South Carolina, the public remains largely unaware of the risks. In the study, over 1,000 members of the public were telephoned and 62 per cent said they were not knowledgeable about OHNC. Among smokers, the lack of awareness ran at 58 per cent. Under half of non-smokers and smokers knew that smoking was a risk factor. Hoarseness was correctly identified as a symptom by only one per cent of smokers and two per cent overall. But 17 per cent of the sample incorrectly named headache as a symptom. People can spot the signs and symptoms of OHNC themselves, but 94 per cent had not been told to look for problems like mouth sores that do not heal. And only 26 per cent had been check for this by a doctor. Clearly there is some way to go in raising awareness among the public of OHNC.

2013-05-14T08:35:21-07:00May, 2013|Oral Cancer News|
Read More

Michael Douglas: It took doctors nine months to figure out walnut-sized tumor at the back of my tongue was throat cancer

Source: www.nydailynews.com Author: Corky Siemaszko Michael Douglas said the tumor at the back of his tongue was the size of a walnut, but it still took doctors nine months to figure out it was throat cancer. “I knew something was wrong,” he said. “My tooth was really sore, and I thought I had an infection.” But the ear-nose-and-throat doctors and periodontists he consulted kept giving him antibiotics. “And then more antibiotics, but I still had pain,” he said. Finally, in 2010, a doctor in Montreal figured out that thing on his tongue was tumor. “Two days later, after the biopsy, the doctor called and said I had to come in,” Douglas recalled in a wide-ranging interview with New York magazine. “He told it me it was stage-four cancer. I said, ‘Stage four. Jesus.’ “And that was that. After complaining for nine months and them not finding anything, and then they told me I was stage four? That was a big day.” Douglas not only talked about his brush with mortality, he also chatted about his Hollywood comeback. He plays flamboyant piano tickler Liberace in an HBO biopic, “Behind the Candelabra,” that airs May 26. “Liberace loved sex,” he said. But the “Wall Street” star’s revelation that he had cancer sent a scare through Hollywood, where the words “stage four” were looked at as a death sentence. And for a time, Douglas looked like hell — losing 45 pounds as he subsisted on mostly on matzo ball soup as he healed. [...]

2013-05-14T08:31:53-07:00May, 2013|Oral Cancer News|
Read More

Study examines role of DNA, HPV in oral cancer survival

Source: www.drbicuspid.com Author: DrBicuspid Staff High-risk types of human papillomavirus (HPV) are increasingly associated with oropharyngeal squamous cell carcinoma (OPSCC). However, HPV-positive OPSCC is highly curable, and patients with HPV have better survival compared with HPV-negative patients, whose cancers are usually associated with alcohol and tobacco use. To better understand the molecular mechanisms underlying these differences, Jochen Hess, PhD, and colleagues at University Hospital Heidelberg monitored changes in DNA modifications in HPV-positive and HPV-negative OPSCCs (Journal of Clinical Investigation, May 1, 2013). They applied an array-based approach to monitor global changes in CpG island hypermethylation between HPV-negative and HPV-positive OPSCCs, and identified a specific pattern of differentially methylated regions that critically depends on the presence of viral transcripts. This DNA modification pattern was significantly correlated with improved survival in three separate groups of OPSCC patients, the researchers noted. "Our study highlights specific alterations in global gene promoter methylation in HPV-driven OPSCCs and identifies a signature that predicts the clinical outcome in OPSCCs," they concluded.

2013-05-14T06:56:32-07:00May, 2013|Oral Cancer News|
Read More

When a virus causes cancer, surgical robot can help

Source: www.bizjournals.com Author: James Ritchie Dr. Keith Wilson finds robotic surgery to be a good approach for removing tumors growing deep in the throat, as I recently reported. As it turns out, such tumors are often part of an alarming trend. They’re often caused by the sexually transmitted human papillomavirus, also known as HPV. In decades gone by, oral cancer was almost always associated with tobacco and alcohol use. It was typically a disease of old men. No more. Many of Wilson’s patients are nonsmokers and very light drinkers. “I can’t tell you how surprised people get,” said Wilson, who is chief of staff at University of Cincinnati Medical Center. “We’re seeing younger, more affluent and more highly educated patients.” High-risk HPVs cause virtually all cervical cancers. They have in recent years been implicated in oropharyngeal cancers. The oropharynx is the middle part of the throat, including the soft palate, the base of the tongue and the tonsils. About 63 percent of oropharyngeal cancers, or 11,000 cases per year, are associated with HPV infection, according to the American Dental Association. They’re frequently under age 50. Fortunately for such patients, HPV-associated oropharyngeal cancers have a better prognosis than those with other causes. Wilson said that cure rates can approach 90 percent. The da Vinci surgical robot is an effective tool for removing them, he said, because its long, joined arms can go where a surgeon’s hands can’t. But the machines, made by Sunnyvale, Calif.-based Intuitive Surgical Inc., are gaining some criticism. [...]

2013-05-03T14:06:57-07:00May, 2013|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top